Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis India Managing Director Shailesh Ayyangar On Building Infrastructure In India To Bring Affordable Drugs To Patients In Rural Markets: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Sanofi-Aventis has had an interesting past in India from having a discovery research center to creating some of the most recognized pharmaceutical brands. But its Managing Director Shailesh Ayyangar is not resting on those achievements. The senior executive who started with Ranbaxy and also worked at SmithKline Beecham in key positions is now taking up the daunting challenge of creating a new paradigm in the rural centers of India. An exercise that requires huge investments, navigation of unseen opposition along with perseverance to witness a real change excites Ayyangar. In a rare interview, Ayyangar spoke to PharmAsia News' India Bureau about the company's rural markets strategy, creating brands, doing research deals and also about buying out "strategically important" companies.

You may also be interested in...



Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan

Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan

Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan

Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan

Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities

MUMBAI - An extensive worldwide search for novel agents to treat chronic neuropathic pain has brought together Sanofi-Aventis and Indian drug maker Glenmark Pharma through a development and commercialization deal for transient receptor potential vanilloid (TRPV3) antagonist molecules

Related Content

UsernamePublicRestriction

Register

SC074272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel